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ABSTRACT
The outcome of steroid-dependent or frequently relapsing nephrotic syndrome of minimal change disease
(MCD), mesangial proliferative GN (MesGN), or FSGS may be poor and with major treatment toxicity. This
academic, multicenter, off-on trial (ClinicalTrials.gov #NCT00981838) primarily evaluated the effects of rituximab
therapy followed by immunosuppression withdrawal on disease recurrence in 10 children and 20 adults with
MCD/MesGN (n=22) or FSGS who had suffered $2 recurrences over the previous year and were in steroid-
induced remission for $1 month. Participants received one dose (n=28) or two doses of rituximab (375 mg/m2
intravenously). At 1 year, all patientswere in remission: 18were treatment-free and15never relapsed.Compared
with the year before rituximab treatment, total relapses decreased from 88 to 22 and the per-patient median
number of relapses decreased from2.5 (interquartile range [IQR], 2–4) to 0.5 (IQR, 0–1;P,0.001) during 1 year of
follow-up. Reductionwas signiﬁcant across subgroups (children, adults, MCD/MesGN, and FSGS; P,0.01). After
rituximab, the per-patient steroid maintenance median dose decreased from 0.27 mg/kg (IQR, 0.19–0.60) to
0 mg/kg (IQR, 0–0.23) (P,0.001), and the median cumulative dose to achieve relapse remission decreased from
19.5 mg/kg (IQR, 13.0–29.2) to 0.5 mg/kg (IQR, 0–9.4) (P,0.001). Furthermore, the mean estimated GFR in-
creased from111.3625.7 to 121.8629.2ml/minper 1.73m2 (P=0.01), with the largest increases in children and in
FSGS subgroups. The mean height z score slope stabilized in children (P,0.01). Treatment was well tolerated.
Rituximab effectively and safely prevented recurrences and reduced the need for immunosuppression in steroid-
dependent or frequently relapsing nephrotic syndrome, and halted disease-associated growth deﬁcit in children.
J Am Soc Nephrol 25: 850–863, 2014. doi: 10.1681/ASN.2013030251
Idiopathic nephrotic syndrome (NS) in children
and young adults is almost invariably the clinical
counterpart of a continuum of glomerular diseases
ranging from the relatively frequent minimal
change disease (MCD) and the less frequent me-
sangial proliferative GN (MesGN), which are pre-
dominantly observed in children, to the relatively
uncommon FSGS that is observed more frequently
in adult patients.1 In a small minority of patients
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that are generally resistant to immunosuppressive therapies,
the disease is due to molecular defects of one of the podocyte
genes.2 In all of the other cases, it appears to be immune-
mediated, but the pathophysiologic process underlying glo-
merular injury remains poorly understood.3
Independent of the underlying renal pathology, prednisone
continues to be the cornerstone treatment at disease onset,
achieving remission within 4 weeks in approximately 90% of
children with MCD and in 20%–60% of those with FSGS.4,5
However, 60%–70% of patients relapse after steroid tapering
or withdrawal, and most require repeat courses of prednisone
to achieve remission of recurrent episodes and/or the addition
of other immunosuppressive medications, such as calcineurin
inhibitors, mycophenolate mofetil, or alkylating agents, to re-
duce the number of relapses and prevent major side effects of
steroid treatment.6 According to their relapse rate, these pa-
tients are classically labeled as “steroid-dependent” or “fre-
quently relapsing”. In these patients, serious adverse effects
of treatment associate with complications of relapsing epi-
sodes of heavy proteinuria. These are the patients in most
urgent need of more effective and safer treatment.
The possibility of a speciﬁc and, hope-
fully, safer approach to patients with steroid-
dependent or frequently relapsing NS
emerged in 2004 when the B cell–depleting
mAb rituximab was reported to induce re-
mission of proteinuria in a child with fre-
quently relapsing NS secondary to MCD
who had received this medication to
cure a supervened idiopathic thrombocyto-
penic purpura.7 Subsequent uncontrolled
observations found some effect of rituximab
in patients with steroid-dependent or
frequently relapsing MCD,8–11 suggesting
that B-cell immunity could play a key role
in the pathophysiology of the disease. Con-
trolled studies in support of this hypothesis,
however, have been both scanty and almost
conﬁned to children12,13 or to patients with
MCD who were evaluated in the context
of a retrospective, observational design.14
Indeed, less attention was given to adults
and patients with FSGS given difﬁculties
in designing adequately powered trials.
Here, we designed a longitudinal, off-on
study (ClinicalTrials.gov #NCT00981838)
to evaluate the efﬁcacy of rituximab in
reducing the incidence of relapses and need
for steroid and other immunosuppressive
medications in children and adults with
steroid-dependent or frequently relapsing
NS due to MCD, MesGN, or FSGS. To
minimize the side effects and costs of
rituximab, we abandoned the standard
four-dose protocol originally implemented
for the treatment of B-cell lymphomas,15 and adopted a new B
cell–driven regimen we found to achieve remission of NS in
patients with idiopathic membranous nephropathy (IMN) as
effectively as the standard protocol, but with fewer side effects
and less costs.16
RESULTS
Overall, 32 of 44 screenedpatients fulﬁlled the selection criteria
and consented to study participation (Figure 1). Two patients
withdrew their consent before rituximab administration.
Thus, 30 patients received one (n=28) or two (n=2) 375 mg/m2
rituximab infusions from April 2009 to January 2011. They had
been receiving chronic therapy with steroids and/or other immu-
nosuppressants over a median of 8.5 years (interquartile range
[IQR], 4.6–15.4) and 3.9 years (IQR, 1.2–6.6), respectively.
Study Population
All patients were Caucasian, with the exception of one Indian
participant.Of treated patients, 10were children (,18 years old)
Figure 1. Study ﬂow chart. Of 44 screened patients, 32 fulﬁll the selection criteria and
30 consent to study participation. Of them, 14 never relapse despite completed
withdrawal of steroid and any other immunosuppressant.
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and 20 were adults. All children were steroid-dependent and 5
adults were frequently relapsing; 19 patients were diagnosed
with MCD, 3 with MesGN, and 8 with FSGS. Patients with
MCD andMesGNwere considered in the same diagnosis group
(Table 1). Median duration of the disease (8.5 years; IQR, 4.6–
15.4 years) tended to be longer in adults and in patients with
FSGS compared with children and those with MCD/MesGN.
At inclusion, all patients were in complete (n=28) or partial
(n=2) remission from theirNS. Serumalbumin and total proteins
were consistently in the normal range in all considered groups
(Table 2). Most participants tended to be overweight and dyslipi-
demic, and most children showed features of hypercorticism.
Children were small for age; according to the Tanner criteria,17
one child was growth retarded. One participant was prepubertal
at the age of 19 years. Eight children and 11 adults were taking BP-
lowering therapy with one or more medications (Table 3).
Previous and Concomitant Immunosuppression
All patients hadbeen treatedwith steroids in thepast (Table 1). In
addition, 25 patients, including all 10 children, had received at
least one course of immunosuppressive steroid-sparing agents.
In particular, 18, 17, and 11 patients had also received one or
more courses of calcineurin inhibitors or antiproliferative or
cytotoxic drugs, respectively. Two patients had been also treated
with levamisole and one with adrenocorticotropic hormone.
At the time of rituximab administration, 29, 10, and 13
patients were taking concomitant steroids, calcineurin inhib-
itors, or antiproliferative agents, respectively. Six and eight
patients were receiving combined treatment with two or three
medications, including steroids. All patients receiving triple
therapy were children (Table 3).
Primary End Point
Relapse of NS
Overall, we observed 110 relapses: 88 before and 22 after
rituximab administration (Figure 2). In four patients, NS
relapsed shortly (3, 5, 7, and 16 days, respectively) after rit-
uximab administration, when circulating B cells were still
fully depleted. The per-patient median number of events
decreased from 2.5 (IQR, 2–4) before rituximab administra-
tion to 0.5 (IQR, 0–1) after rituximab administration.
Among patients with 2, 3, or more relapses over the year
before rituximab administration, the number of events
over the year after rituximab administration decreased to
0 (IQR, 0–1), 1 (IQR, 0–1), and 1 (IQR, 1–2) with a relative
event number reduction of 100% (IQR, 50%–100%), 66.7%
(IQR, 66.7%–100%), and 75% (IQR, 71.4%–80%), respec-
tively. This 5-fold reductionwas highly signiﬁcant (P,0.001)
in the study group as a whole as well as in children and adults or
MCD/MesGN and FSGS patients considered separately (Figure
Table 1. Baseline patient characteristics in the study group as a whole (overall) and according to age and diagnosis group
Characteristic
Overall
(N=30)
Children
(n=10)
Adults
(n=20)
MCD/MesGN
(n=22)
FSGS
(n=8)
Demographics
Age (yr) 22.7 (13.6–43.0) 11.7 (9.5–13.6) 34.3 (22.7–47.4) 22.7 (13.6–43.0) 21.6 (14.2–46.1)
Male sex 15 (50) 5 (50) 10 (50) 11 (50) 4 (50)
Caucasian 29 (96.7) 10 (100) 19 (95) 21 (95.5) 8 (100)
Smoker 8 (26.7) 0 8 (40) 6 (27.3) 2 (25)
Disease characteristics
Age at onset of nephropathy 6.5 (2.8–33.4) 3.1 (2.2–5.7) 20.6 (4.3–39.8) 6.5 (2.8–23.1) 7.2 (2.6–36.4)
,18-yrs-old at onset 18 (60) 10 (100) 8 (40) 13 (59) 5 (63)
Duration of disease (years) 8.5 (4.6–15.4) 7.1 (6.1–10.4) 10.3 (3.4–20.0) 7.7 (4.6–15.4) 10.3 (5.1–15.9)
Steroid-dependent NS versus frequently
relapsing NS
25 versus 5 10 versus 0 15 versus 5 18 versus 4 7 versus 1
MCD/MesGN versus FSGS 7 versus 3 15 versus 5
Children versus adults 7 versus 15 3 versus 5
Age at onset (,18 yr) 18 (60) 10 (100) 8 (40) 13 (59) 5 (63)
Previous immunosuppressive treatments
Oral steroids 30 (100) 10 (100) 20 (100) 22 (100) 8 (100)
Calcineurin inhibitors 18 (60.0) 9 (90.0) 9 (45.0) 11 (50.0) 7 (87.5)
Cyclosporine 18 (60) 9 (90) 9 (45) 11 (50) 7 (87.5)
Tacrolimus 2 (6.7) 2 (20) 0 0 2 (25)
Antiproliferative or cytotoxic agents 17 (56.7) 8 (80.0) 9 (45.0) 12 (54.5) 5 (62.5)
Azathioprine 4 (13.3) 3 (30) 1 (5) 3 (13.6) 1 (12.5)
Cyclophosphamide 11 (36.7) 4 (40) 7 (35) 8 (36.4) 3 (37.5)
Mofetil mycophenolate 16 (53.3) 7 (70) 9 11 (50) 5 (62.5)
At least one steroid-sparing agent
during the past
25 (83.3) 10 (100) 15 (75) 17 (77.3) 8 (100)
Data are presented as the median (IQR) or n (%).
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2), even when the last recurrence immedi-
ately preceding rituximab administration
was not considered (P,0.001).
Patients with Relapse
Only 15 of the 30 study patients had one or
more relapses over 1 year after rituximab
therapy, whereas all of themhad had at least
tworelapsesduring theyear before rituximab
therapy (P,0.001). Thus, after rituximab
administration, 15 patients were persis-
tently relapse-free throughout the whole
observation period. At the study end, 14
of these patients were fully off steroids and
any other concomitant immunosuppres-
sive medication (Figure 1). Relapses after
rituximab therapy were observed in 7 of
10 children (70%) compared with 8 of 20
adults (40%), as well as in 12 of 22 patients
with MCD/MesGN (54.5%) compared
with 3 of 8 patients with FSGS (37.5%).
The trend toward more relapses in children
and inMCD/MesGNpatients after rituximab
administration paralleled the higher incidence
Table 3. Patients on concomitant immunosuppressive and supportive treatment at baseline and at 1-year follow-up in the
study group as a whole (overall) and according to age and diagnosis group
Treatment
Overall (N=30) Children (n=10) Adults (n=20) MCD/MesGN (n=22) FSGS (n=8)
Baseline 1 yr Baseline 1 yr Baseline 1 yr Baseline 1 yr Baseline 1 yr
Immunosuppressive drugs (n)
None 0 18 (60) 0 4 (40) 0 14 (70) 0 12 (54.5) 0 6 (75)
Steroid alone 15 (50) 6 (20) 1 (10) 1 (10) 14 (70) 5 (25) 11 (50) 6 (27.3) 4 (50) 0
Any steroid-sparing agent 15 (50) 6 (20) 9 (90) 5 (50) 6 (30) 1 (5) 11 (50) 4 (18.2) 4 (50) 2 (25)
Steroid + 1 7 (23.3)a 6 (20) 1 (10) 5 (50) 6 (30)a 1 (5) 5 (22.7)a 4 (18.2) 2 (25) 2 (25)
Steroid + 2 8 (26.7) 0 8 (80) 0 0 0 6 (27.3) 0 2 (25) 0
Immunosuppressive treatment
Oral steroids 29 (96.7) 12 (40) 10 (100) 6 (60) 19 (95) 6 (30) 21 (95.4) 10 (45.5) 8 (100) 2 (25)
Calcineurin inhibitors 10 (33.3) 0 9 (90) 0 1 (5) 0 7 (31.8) 0 3 (37.5) 0
Cyclosporine 9 (30) 0 8 (80) 0 1 (5) 0 7 (31.8) 0 2 (25) 0
Tacrolimus 1 (3.3) 0 1 (10) 0 0 0 0 0 1 (12.5) 0
Antiproliferative or
cytotoxic agents
13 (43.3) 6 (20) 8 (80) 5 (50) 5 (25) 1 (5) 10 (45.5) 4 (18.2) 3 (37.5) 2 (25)
Mycophenolate mofetil 11 (36.7) 6 (20) 7 (70) 5 (50) 4 (20) 1 (5) 8 (36.4) 4 (18.2) 3 (37.5) 2 (25)
Azathioprine 1 (3.3) 0 1 (10) 0 0 0 1 (4.5) 0 0 0
Cyclophosphamide 1 (3.3) 0 0 0 1 (5) 0 1 (4.5) 0 0 0
Supportive treatment
Antihypertensive drugs 19 (63.3) 17 (56.7) 8 (80) 8 (80) 11 (55) 9 (45) 13 (59.1) 11 (50) 6 (75) 6 (75)
Diuretics 4 (13.3) 3 (10) 0 0 4 (20) 3 (15) 3 (13.6) 2 (9.1) 1 (12.5) 1 (12.5)
b-Blockers 1 (3.3) 1 (3.3) 0 0 1 (5) 1 (5) 1 (4.5) 1 (4.5) 0 0
Calcium channel blockers 3 (10) 1 (3.3) 3 (30) 1 (10) 0 0 2 (9.1) 1 (4.5) 1 (12.5) 0
ACE inhibitors 12 (40) 13 (43.3) 4 (40) 5 (50) 8 (40) 8 (40) 8 (36.4) 8 (36.4) 4 (50) 5 (62.5)
Angiotensin receptor
antagonists
7 (23.3) 5 (16.7) 4 (40) 3 (30) 3 (15) 2 (10) 3 (13.6) 2 (9.1) 4 (50) 3 (37.5)
Data are presented as n (%). ACE, angiotensin converting enzyme.
aIncluding one adult on cyclophosphamide alone.
Figure 2. Box plot of the number of NS relapses over 1 year of follow-up after rit-
uximab administration, and during the year before rituximab administration in the study
group as a whole (overall), and in different age (children versus adults) and diagnosis
(MCD/MesGN versus FSGS) subgroups considered separately.
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of events observed in both subgroups before rituximab admin-
istration (Figure 2).
The median time to the ﬁrst event (7.5 months; IQR,
0.5–10.7; Figure 3, upper panel) did not differ appreciably
among subgroups (Figure 3, middle and lower panels) as
well as between patients with or without childhood disease
onset (Supplemental Figure 1).
Predictors of Relapse
Younger age at inclusion signiﬁcantly correlated with a higher
number of relapses before rituximab administration
(r=20.58; P,0.001). A similar correlation was found be-
tween age at disease onset and number of relapses that, how-
ever, was only marginally signiﬁcant (r=20.36, P=0.05).
None of the two covariates correlated with the event number
after rituximab administration (r=20.30, P=0.11; and
r=0.30, P=0.11, respectively) or with relative event reduction
versus before rituximab administration (r=0.22, P=0.24; and
r=0.31, P=0.09, respectively).
We used ﬁrst-order fractional polynomials to model non-
linear continuous baseline predictors in the Cox analysis.
Univariate analysis showed that age at inclusion (P=0.02), age
at disease onset (P=0.10), and the event number over the year
before rituximab administration considered as a continuous
(P,0.05) or dichotomous (P=0.03) variable were signiﬁcantly
associated with the risk of relapse after rituximab administra-
tion (Supplemental Table 1).Multivariate analysis showed that
age at disease onset retained a signiﬁcant association with the
outcome when adjusted for the previous number of relapses
considered either as an ordinal (P=0.04) or dichotomous
(P=0.04) variable. With both models, the association of pre-
vious relapses with the outcome was borderline signiﬁcant
(Supplemental Table 1).
Anthropometric, Clinical, and Laboratory Parameters
Children versus Adults
After rituximab administration, children resumed a normal
or near normal growth rate that averaged 4.462.0 cm over
the 1-year follow-up. Consistently, their height signiﬁcantly
increased; combined with the parallel reduction in weight,
these results translated into a signiﬁcant reduction in body
mass index at 1 year compared with baseline (Table 2).
These anthropometric changes were paralleled by a con-
comitant increase in estimated GFR at 1 year compared
with baseline (Table 2). BP control also remarkably im-
proved on follow-up, whereas other considered parameters
did not change appreciably (Table 2). In adults, no consid-
ered parameter changed appreciably, with the exception of
serum total protein and triglyceride levels, which signiﬁ-
cantly increased and decreased at 1 year compared with
baseline, respectively. In the 11 adults with measured io-
hexol plasma clearance, the GFR averaged 100.2629.1 ml/
min per 1.73 m2 at 1 year and albumin and sodium frac-
tional clearances (data not shown) did not change apprecia-
bly compared with baseline.
MCD/MesGN Versus FSGS
Time-dependent changes in all considered parameters did not
differ appreciably between the two diagnosis groups (Table 2).
Figure 3. Time to NS relapse was similar between age and di-
agnosis groups. Kaplan–Meier curves showing the proportion of
participants progressing to the ﬁrst NS relapse at different time
points over 1 year of follow-up after rituximab administration in the
study group as a whole (overall, upper panel) and in different age
(children versus adults) and diagnosis (MCD/MesGN versus FSGS)
subgroups considered separately (middle and lower panels, re-
spectively). 95% CI, 95% conﬁdence interval; HR, hazard ratio.
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B-Cell Counts
After rituximab administration, CD19 B lymphocytes were
promptly and fully depleted and progressively reemerged into
the circulation from month 6 to 1 year (Figure 4). In partic-
ipants without relapses, the reduction in circulating B cells at
different time points versus baseline was signiﬁcant
throughout the whole study period, whereas the difference
was not signiﬁcant any longer from day 240 up to the study
end in those patients with relapses.
Concomitant Therapy
Steroids and Other Immunosuppressive Medications
At 1 year, 18 patients (60%) had completed tapering and
withdrawal of all immunosuppressive medications (Figure 1,
Table 3). Of these patients, 14 (77.8%) had completed treat-
ment withdrawal without any disease recurrence throughout
the whole observation period (Figure 1). Thus, at 1 year, only
12 patients were receiving maintenance immunosuppression.
Six of these patients were taking a steroid combined with other
immunosuppressants compared with 15 patients who were
taking combined therapy at baseline (Figure 5, Table 3). Five
of the patients taking residual combined therapy were chil-
dren. Of note, all 10 patients taking calcineurin inhibitors at
baseline had withdrawn these medications at 1 year (Table 3).
Thus, the number of patients requiring maintenance immu-
nosuppression with steroid alone or in combination with one
or two additional immunosuppressive medications remark-
ably decreased after rituximab administration compared with
baseline (Figure 5). Consistently, the per-patient median ste-
roid daily dose signiﬁcantly decreased from 0.27 mg/kg (IQR,
0.19–0.60) to 0 mg/kg (IQR, 0–0.23) (P,0.001) at 1 year
compared with baseline (Figure 6, left panel). The dose sig-
niﬁcantly decreased from 0.53 mg/kg (IQR, 0.27–0.82) to
Figure 4. Circulating B cells at the time of rituximab adminis-
tration (day 0) and at different time points thereafter in participants
with or without relapses of NS throughout the 1-year observation
period. Up to day 210, B-cell counts are always signiﬁcantly lower
compared with baseline in both groups. From day 240 to day 365
differences were still signiﬁcant versus baseline in nonrelapsers,
but were no longer signiﬁcant in relapsers.
Figure 5. Rituximab reduced the need for maintenance immunosuppression. Numbers of patients with any maintenance immuno-
suppressive therapy (left), or on maintenance therapy with steroid alone (middle), or steroid plus one or two additional immunosup-
pressive medications (right) at the time of rituximab administration (baseline) and at 1 year after treatment administration.
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0.25 mg/kg (IQR, 0.13–0.45) (P=0.03), even when the com-
parison was restricted to the 12 patients who were still taking
maintenance steroid therapy at 1 year. Cumulative yearly doses
of mycophenolate mofetil and cyclosporin A also decreased
from 304.5 g (IQR, 140.0–496.5) to 195.0 g (IQR, 112.5–
255.0), and from 39.92 g (IQR, 32.76–46.15) to 14.85 g
(IQR, 11.55–18.00) (P=0.04 and P=0.01, respectively).
All relapses observed over each year before or after
rituximab administration were treated with a standardized
steroid regimen as per center practice, and no patient was
exposed to repeated rituximab courses to prevent or treat
recurrences.Themedian cumulativedoseof steroid required to
induce remission of all relapses observed over 1 year before
and after rituximab administration largely decreased from
56.8 mg/kg (IQR, 34.4–93.7) to 0.5 mg/kg (IQR, 0–18.1)
(P,0.001; Figure 6, middle panel). This reduction reﬂected
the reduced number of relapses after rituximab (Figure 2), as
well as the concomitant reduction from 19.5 mg/kg (IQR,
13.0–29.2) to 0.5 mg/kg (IQR, 0–9.4) (P,0.001) of the median
cumulative dose required to achieve remission of each single
relapse (Figure 6, right panel). This reduction, in turn, was
partly explained by the reduced median duration of relapses
from 15 days (IQR, 14–27) to 11.5 days (IQR, 7–16) (P=0.02).
Concomitant Medications
In parallel with tapering and withdrawal of steroid therapy,
fewer patients required concomitant therapy with protonic
pump inhibitors and other gastroprotective medications at
follow-up compared with baseline. No
substantial changes in angiotensin convert-
ing enzyme inhibitor or angiotensin re-
ceptor blocker therapy were introduced
during the study (Table 3).
Adverse Events
No serious treatment-related adverse event
was observed during, or shortly after,
rituximab infusion.During the observation
period, eight serious adverse events were
reported in six adults. All events occurred in
patients still receiving concomitant therapy
with steroid and other immunosuppressive
medications, and patients recovered with-
out sequelae (Table 4). No child had serious
adverse events.
Extension
Additional sensitivity analyses considering
an extended observation period, ranging
from 2 years before rituximab administra-
tion to 2 years thereafter, conﬁrmed the
Figure 6. Rituximab allowed to signiﬁcantly reduce the steroid therapy doses. Box plot of
per-patient daily steroid maintenance dose administered to prevent NS recurrences at the
time of rituximab administration (baseline) and at 1 year after treatment administration (left),
and cumulative steroid dose administered to treat all NS recurrences (middle) and each single
NS recurrence (right) observed over 1 year of follow-up after rituximab administration and
during the year before rituximab administration. All data are adjusted for patient body weight.
Table 4. Serious adverse events over 1 year of follow-up in the study group as a whole (overall) and according to age and
diagnosis group
Serious Adverse Event
Overall
(N=30)
Children
(n=10)
Adults
(n=20)
MCD/MesGN
(n=22)
FSGS
(n=8)
Infectious
Acute gastroenteritis 2 (6.7) 0 2 (10.0) 1 (4.5) 1 (12.5)
Varicella 1 (3.3) 0 1 (5.0) 0 1 (12.5)
Flu-like syndrome 1 (3.3) 0 1 (5.0) 1 (4.5) 0
Non-otherwise-speciﬁed viral infectiona 1 (3.3) 0 1 (5.0) 0 1 (12.5)
Noninfectious
Seizures 1 (3.3) 0 1 (5.0) 1 (4.5) 0
Biliary colic 1 (3.3) 0 1 (5.0) 1 (4.5) 0
Melanoma in situ 1 (3.3) 0 1 (5.0) 1 (4.5) 0
Patients with at least one eventb 6 (20.0) 0 6 (30.0) 5 (22.7) 1 (12.5)
Data are presented as n (%). No event was observed in children. No infectious event was observed after completion of immunosuppression tapering and with-
drawal. All patients with events fully recovered.
aCharacterized by lymphopenia, fever, and gingivitis.
bThree events (gastroenteritis, viral infection, varicella) occurred in the same young adult.
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event number reduction observed during the core study
(Figure 7). The number of events observed during the ﬁrst
year (0.5; IQR, 0–1) and the second year (0; IQR, 0–1) after
rituximab both signiﬁcantly decreased compared with the
event number observed during the two 1-year periods before
rituximab (1; IQR, 1–3; and 2.5; IQR, 2–4, respectively;
P,0.01 for all comparisons between periods before and after
rituximab administration). The event reduction observed af-
ter rituximab administration was sustained up to 2 years of
follow-up.
Post hoc analyses considering the children’s height z scores
over 3 years before and after rituximab treatment showed a
progressively increasing growth deﬁcit over the 3 years pre-
ceding rituximab administration, a trend that was fully blun-
ted by rituximab administration that stabilized the height
z score over the following 3 years (Figure 7, left panel). Con-
sistently, the mean height z score slope signiﬁcantly (P,0.01)
improved from 20.0260.004 to 20.00160.006 per month
(Figure 7, right panel). Virtually identical results were ob-
tained when the D z score between the height z score and
the target height z score was considered (data not shown).
The change in D z score slope after rituximab administration
was signiﬁcant as well (P,0.01). Of note, no treatment effect
was observed in two girls who had progressed to Tanner stage 5
(puberty) at the time of rituximab administration.
DISCUSSION
In this longitudinal, within-patient controlled study, we found
that the anti-CD20 mAb rituximab signiﬁcantly reduced the
frequency of relapses in 10 children and 20 adults with steroid-
dependent or frequently relapsing NS, and was safe. Over a
1-year observation period, relapses decreased by approxi-
mately 5-fold compared with the year preceding rituximab
treatment, an effect that was independent of the number of
relapses before inclusion andwas similar in children compared
with adults as well as in patients with MCD or MesGN
considered as awhole compared with those with FSGS. Similar
results were obtained when the observation period was
extended from 2 years before to 2 years after rituximab
administration. These additional sensitivity analyses con-
ﬁrmed that study ﬁndings were robust and showed that the
treatment effect was sustained over time.
Of note, at the study end, all participants were in remission
and 18 patients were free of any immunosuppressive medica-
tion. Theﬁnding that 14 of the 18 treatment-free patients never
relapsed after rituximab administration, even after complete
withdrawal of ongoing immunosuppressive therapy, provided
additional evidence of the protective effect of rituximab
prophylaxis against disease recurrence. The marked suppres-
sion of disease activity was conﬁrmed by the reduced need for
maintenance immunosuppression and cumulative steroid
dose required achieving remission of recurrences of NS.
Notably, the steroid-sparing effect was explained not only by
the reduced number of recurrences, but also by the reduced
amount of steroid required to achieve remission of each single
episode. This was a genuine effect of rituximab, because no
speciﬁc guideline for diagnosis and treatment of relapses was
introduced during the study and the investigators were advised
to continue treating recurrences of NS as per center practice. A
plausible explanation is that previous prolonged exposure to
steroidal drugs resulted in a glucocorticoid resistancemediated
by downregulation of glucocorticoid receptor-a and other
mechanisms18 that recovered with steroid
back-titration andwithdrawal after rituximab
administration. On the other hand, the
same mechanisms underlying the protec-
tive effects of rituximab against disease re-
lapses could also limit their severity. Both
the reduced exposure to steroid therapy
and complete withdrawal of calcineurin
inhibitors most likely accounted for the
progressive reduction in BP and the amelio-
ration of dyslipidemia and estimated GFR
that we observed on follow-up, particularly
in children. The ﬁnding that rituximab
fully blunted the progressively increasing
growth deﬁcit observed in children over
3-year steroid exposure and normalized
their growth rate up to the 3-year follow-
up—with the only exception of two girls
who had progressed to Tanner stage 5
and had, therefore, most likely exhausted
their residual growth potential—was
also a ﬁnding of major clinical relevance,
because impaired growth is one of the
Figure 7. Reduction or withdrawal of steroids after rituximab therapy blunted the in-
creasing growth deﬁcit previously observed in children over 3-year steroid exposure and
normalized their growth rate up to the 3-year follow-up. Height z scores (left) and mean
height z score slope (right) during the two 3-year observation periods before and after
rituximab administration in the 10 children with steroid-dependent NS. *P,0.05 versus
month 0; **P,0.01 versus month 0; ○P ,0.05 versus 212 months.
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most devastating effects of chronic steroid therapy.19 Conceiv-
ably, reduced immunosuppressionwill reduce the risk of serious
side effects in the long term,20 particularly in those individuals
progressing to ESRD who eventually receive a kidney transplant
requiring further immunosuppressive treatment to prevent re-
jection21 or to treat post-transplant disease recurrence.
After the ﬁrst occasional observation7 and small uncon-
trolled studies suggesting the efﬁcacy of B-lymphocyte deple-
tion in children with MCD,8,9,11–13 a recent observational
study suggested that rituximab therapy may reduce the inci-
dence of recurrences in adults with the same disease.14 Within
the limitation of the small sample size, comparative analyses
according to patient age either at inclusion or at disease onset
suggest that rituximab treatment may be equally effective in
children and adults, independent of the underlying pathology.
On the other hand, our present data convey the fully novel and
clinically relevant message that rituximab may be uniformly
effective in patients with steroid-sensitive idiopathic FSGS,
regardless of age, which has major clinical relevance. FSGS
remains the ﬁrst cause of ESRD among patients with primary
glomerulopathies and, in the context of idiopathic NS, it carries
the poorest prognosis and highest risk of serious complications
of relapsing proteinuria and heavy immunosuppression.22
These ﬁndings extend previous evidence that rituximab
reduced proteinuria and the need for immunosuppressive
therapy at 3-month follow-up in 54 children with steroid-
dependent idiopathic NS12 and limited the risk of relapses in
17 adults with steroid-dependent MCD,10 whereas it failed to
appreciably affect disease outcome in children with resistant
idiopathic NS.23 The ﬁnding that the treatment effect was sus-
tained over 2 years of follow-up was consistent with recent
evidence that prolonged remission could be achieved with 1–
5 courses of rituximab in a substantial proportion of children
with previous steroid-dependent or calcineurin inhibitor–
dependent NS.24
On the other hand, the ﬁnding that patients with FSGS had
the same response to treatment compared with those with
MCD or MesGN was particularly intriguing. This would
suggest that mechanisms of idiopathic NS are independent of
the underlying pathology, possibly reﬂecting a disease spec-
trum that includes steroid-dependent MCD, MesGN, and
FSGS as different morphologic manifestations of overlapping
etiologic factors.
Disease remissionwas associated with prompt, long-lasting
depletion of circulating B cells, suggesting that, as previously
observed in IMN,16 the treatment effect could be mediated by
disruption of autoreactive B lymphocyte clones producing
pathogenic Igs. From this perspective, we speculate that the
four early recurrences observed within 16 days after rituximab
administration were triggered by preformed antibodies re-
leased into the circulation before treatment-induced B-cell
depletion. Recent evidence that the permeability factor histor-
ically advocated to explain the pathogenesis of glomerular
barrier dysfunction in idiopathic NS25 could be, or could
bind to, an Ig would reconcile the old hypothesis of a key
role for this putative factor with the concept based on present
data that idiopathic NS could be a B cell–related disorder.26
The pathogenic role of B lymphocytes would also explain why
MCD or FSGSmay occasionally occur in patients with other B
cell–mediated diseases27 and why NS remission achieved by
rituximab associates with circulating B-cell depletion.8–14,26 In
patients in this study, persistence of remission after B lympho-
cyte reappearance in the circulation could actually be the re-
sult of a complete and deﬁnitive disruption of the potential
autoreactive clone(s). This is in line with the evidence that in
IMN, persistent remission achieved by rituximab therapy is
paralleled by depletion of nephritogenic autoantibodies, even
after re-emergence of B lymphocytes in the circulation.28 Ad-
ditional mechanisms, including interference with antigen pre-
sentation, expansion of regulatory T cells, or modulation of
natural killer cell and macrophage activity, could underlie the
efﬁcacy of rituximab in this context.29 Finally, rituximab may
directly bind the sphingomyelin phosphodiesterase acid-like
3b protein expressed on the glomerular epithelial cell surface,
an effect expected to stabilize the cytoskeleton and prevent
apoptosis and eventually restore the physiologic barrier
function of the podocyte.30 On the other hand, evidence
that rituximab is not uniformly effective in all cases of steroid-
dependent or frequently relapsing NS may imply different eti-
ologies in some patients, as well as gene-related factors and,
possibly, different susceptibilities of podocytes or podocyte pro-
genitors to injury.
Of note, in 28 of 30 study patients, treatment effect was
achieved by one single 375 mg/m2 rituximab dose. With the
exception of few reports in steroid-dependent MCD,11–13,26
most previous studies tested the standard four weekly 375mg/m2
dose regimen originally implemented for the treatment of re-
lapsing or refractory non-Hodgkin’s lymphoma,15 a regimen,
in several cases, that was followed by additional doses infused in
the attempt to achieve some degree of remission after initial
treatment failure. However, we reasoned that dysfunctional
B-cell mass here is remarkably lower than in B-cell malignan-
cies and that lower doses of rituximab would fully deplete ab-
errant B-cell clones, as previously observed in 36 IMN patients
with long-lasting, persistent NS.16 Consequent advantages in-
cludedminimized risk of infusional reactions, reduced number
of hospitalizations, and savings of .€10,000 (approximately
$13,000) per patient. Minimizing patient exposure will also
limit the risk of acute reactions secondary to patient sensitiza-
tion and of rituximab inactivation by drug-speciﬁc antibodies,
which is instrumental to allow effective retreatment in the case
of disease recurrence. This may be of clinical relevance for
patients with steroid-dependent or frequently relapsing NS
who fail to achieve persistent remission and might, therefore,
require repeated, even life-long, courses of rituximab treat-
ment.
As previously reported in different clinical settings, rituximab
therapy was remarkably safe and well tolerated. No treatment-
related serious adverse event was observed during rituximab
infusion; on the basis of its long-term safe and tolerable
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proﬁle,31 no serious side effects are expected in most patients
over decades. However, post-treatment surveillance is recom-
mended because serious adverse events such as progressive
multifocal leukoencephalopathy have been exceptionally ob-
served even years after exposure in patients with proliferative
disorders and individuals who are heavily immunosup-
pressed.32 Notably, the overall rate of adverse events over the
follow-up period was minimal, and no serious event was ob-
served in children, a ﬁnding attributable to reduced incidence
of relapses on top of reduced exposure to steroids and immu-
nosuppressive therapy. Consistently, no event was observed
after completion of treatment withdrawal in the 18 patients
who achieved this goal.
The major limitation of this study was that treatment was
not assigned according to a randomized design. A randomized
parallel group study, however, would have required a much
larger number of patients to provide the analyses with an
adequate power to detect a treatment effect despite wide
interpatient variability. Because of the rarity of the disease,
particularly of adult and FSGS cases, this approachwould have
reduced the feasibility of the study. A longitudinal design with
intrapatient comparisons in a well characterized population
with adocumentedhigh rate of disease recurrences remarkably
increased the statistical power of the study, which allowed
addressing the working hypothesis even in a resource-limited
setting. The striking, 5-fold relapse reduction observed shortly
after rituximab administration was consistent through all
considered subgroups and closely reproduced the treatment
effect reported in previous retrospective observational analy-
ses.10 The above ﬁndings cannot be explained by a spontane-
ous trend of the disease towane over time, a process occasionally
observed in some patients over several years and even decades.
Any appreciable confounding effect of regression to the mean
was excluded by ﬁnding that a similar and highly signiﬁcant
treatment effect on the relapse rate was also observed when
the observation period was extended over 2 years before
and after rituximab treatment and relapse episodes immediately
preceding rituximab administration were not considered in
comparative analyses. The ﬁnding that event reduction was sig-
niﬁcant despite the theoretical possibility that retrospectively
recorded before rituximab relapses could have been underesti-
mated provided additional evidence of the robustness of the
results.
The power of comparative analyses between different
considered subgroups was limited by the small sample size,
thus the possibility that treatment effect could be affected by
patient age or underlying pathology could not be deﬁnitely
excluded.
Rituximab treatment effectively reduced the incidence of
recurrences and theneed for eithermaintenance and induction
immunosuppression in patients with steroid-dependent or
frequently relapsing idiopathic NS, and allowed patients to
maintain sustained remission without any immunosuppres-
sion in most cases. Treatment was remarkably safe and well
tolerated in all patients. These ﬁndingsmay havemajor clinical
implications, because rituximab therapy might help limit the
complications of NS and of concomitant treatments, compli-
cations that are often devastating in this clinical context. Our
ﬁndings may provide the background for future pathophys-
iology studies to further investigate the mechanisms under-
lying the effects of rituximab therapy in patients with
idiopathic NS and to identify early predictors of response to
rituximab therapy in this context.
CONCISE METHODS
Study Population
We included patients with steroid-dependent or frequently relapsing
NS (see the “deﬁnitions” paragraph) secondary to biopsy-proven
MCD, MesGN, or FSGS who had suffered at least two recurrences
of NS over the last year despite steroid and/or other immunosuppres-
sive therapy, were in steroid-induced partial or complete remission
since at least 1 month from the last recurrence, had a creatinine
clearance.20 ml/min/1.73 m2, and had no evidence of hepatitis B
or C virus infection. Patients were not included if they met any of the
following: refractory or persistent NS, genetic mutations associated
with intrinsic abnormalities of the glomerular barrier, legal incapacity,
intellectual disability/mental retardation, dementia, schizophrenia, and
any condition preventing the possibility of providing an informed
consent, or with concomitant clinical conditions that could prevent
completion of the study or jeopardize data interpretation. Pregnant or
lactating women or women with childbearing potential without effec-
tive contraception were also excluded. Detailed selection criteria are
provided at http://www.clinicaltrials.gov/. Written informed consent
was obtained from adult patients or parents of underage patients.
This study was approved by the ethics committees of all participating
centers.
Aims
This study primarily aimed to evaluate the incidence of recurrences of
NS over 1-year follow-up compared with the incidence observed over
the year before rituximab administration. The study also evaluated
and compared the amount of steroid and other immunosuppressive
medications required to achieve and maintain remission of NS over
the year before and after rituximab administration, as well as the
effects of treatment back-titration on clinical and laboratory param-
eters. All outcomeswere evaluated in the study group as awhole and in
different subgroups considered separately. Finally, the study aimed to
evaluate the safety and tolerability of rituximab administration.
Additional sensitivity analyses were performed extending the evalu-
ation of relapses over 2 years before and after rituximab administra-
tion and changes in height z scores and D z scores between height
z scores and target height z scores were compared in children over the
3-year observation periods before and after rituximab treatment.
Retrospective data before rituximab administration were exhaus-
tively recorded through electronic case report forms by the
same doctors who were in charge of patient care in every-day clinical
practice, whereas data after rituximab treatment were recorded pro-
spectively.
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Design
Baseline Evaluations
Before rituximab administration, we measured ofﬁce BP, weight,
height, proteinuria in 24-hour urine collections, serum lipids, and
routine laboratory parameters. In a subgroup of patients, we also
measured the GFR by using the iohexol plasma clearance technique,33
and calculated albumin and Na+ fractional clearances.
Experimental Treatment
After per centers practice premedication with steroids and/or
antihistaminic agents, 375 mg/m2 of rituximab were intravenously
infused through a 0.22-mm in-line ﬁlter after reconstitution in nor-
mal saline to a ﬁnal 1 mg/ml concentration. The infusion was started
at 1 ml/kg per hour and the rate of infusion was progressively in-
creased up to 4 ml/kg per hour according to drug tolerability. An
intensivist attended the start of treatment and was on call throughout
the whole duration of the infusion. Circulating B cells were measured
24 hours after rituximab administration. If.5 B cells per mm3 were
observed, they were again measured 1 week later. If counts were still
.5 B cells per mm3, a second dose of rituximab was administered
with the same identical modalities applied during the ﬁrst infusion.
Concomitant Therapy and Follow-Up
Starting at 1 month after rituximab administration, concomitant
immunosuppression was progressively back-titrated over 6–9 months,
up to complete treatment withdrawal or recurrence of NS. Recurrences
were treated per center’s practice. Per protocol, immunosuppressive
medications, including calcineurin inhibitors, mycophenolate mofetil,
or alkylating agents, were taperedﬁrst in patients receiving dual or triple
maintenance therapy. Steroid tapering was started only after all other
immunosuppressive medications had been withdrawn.
No speciﬁc guideline for diagnosis or treatment of NS relapses was
introduced during the study and the study centers were advised to
continue treating relapsing as per center practice.
No change in diet and other therapies, particularly with angiotensin
converting enzyme inhibitors or angiotensin II receptor blockers, was
systematically introduced throughout the whole study period.
Urine was closely tested by Albustix during back-titration of
immunosuppressive and steroid therapy and whenever deemed
clinically appropriate thereafter. Proteinuria and CD20 or CD19 B
cells were measured at monthly visits. All baseline evaluations were
repeated at 1 year after rituximab administration (ﬁnal visit).
Study Conduction
This study was coordinated and monitored by the Department of
Renal Medicine of the IRCCS - Istituto di Ricerche Farmacologiche
“Mario Negri,” Clinical Research Center for Rare Diseases “Aldo e
Cele Daccò” according to good clinical practice guidelines. Data were
locally recorded in dedicated case report forms and then doubly en-
tered in the central database at the Clinical Research Center.
Deﬁnitions
The following deﬁnitions were used: steroid-dependent NS, relapses
invariably observed during steroid tapering or within 2 weeks after
steroid discontinuation34; frequently relapsing NS, $2 relapses
observed over the last 6 months or $4 relapses observed over any
12-month period34; complete or partial remission, proteinuria,0.3 g/24
h (,4 mg/h per m2 in children) or,3.5 g/24 h (,40 mg/h per m2 in
children), respectively, in at least two consecutive visits; and relapse,
recurrence of massive proteinuria (.3.5 g/24 h or .40 mg/h per m2
in children or urine dipstick results$2+ on three consecutive days).
Sample Size Estimation
Themain outcome variable considered for sample size estimationwas
NS recurrence. Per the selection criteria, 100% of study patients were
expected to have at least one relapse over 1 year of observation before
study inclusion. Assuming that rituximab administration would have
reduced thenumberof patientswith at least one recurrence over 1 year
of observation by $50%, we calculated that the inclusion of 16 pa-
tients would have conferred a 90% power to demonstrate a statisti-
cally signiﬁcant reduction (a=0.05, one-tailed test) in the number of
patients with recurrences after rituximab administration. To account
for a 20% dropout rate, screening of participants had to be continued
at least until 20 patients would have been included.
Statistical Analyses
The Kaplan–Meier method was used to plot the probability of achiev-
ing NS relapse. Survival time was determined from the beginning of
the rituximab treatment until the ﬁrst event of interest. Patients not
achieving the event were considered as censored at the time of the last
visit. Time to ﬁrst NS relapse was also analyzed using Cox propor-
tional hazard regression models. Univariate Cox analysis tested sex,
age, age at disease onset, systolic and diastolic BP, serum creatinine,
serum albumin, total cholesterol, triglycerides, diagnosis group,
number of immunosuppressive drugs, median duration of relapse,
and number of relapses during the 1 year before rituximab treatment.
Multivariable Cox analysis included the covariates signiﬁcantly asso-
ciated with the event at the univariable analysis including age at onset
and number of relapse before rituximab treatment in the model. To
model continuous or ordinal predictors within the single models
when the assumption of linearity was found to be untenable, we
used ﬁrst-degree fractional polynomials.35
Normality for continuous variables was assessed by means of the
Q-Q plot. Correlations were performed using Spearman rank
correlation coefﬁcient. Relative event number reduction was deﬁned
as follows: [(number of relapses before rituximab 2 number of re-
lapses after rituximab)/number of relapses before rituximab]. Box
and whisker plots were used to graph skewed distribution. The data
of baseline characteristics were presented as numbers and percen-
tages, means and SDs, or medians and IQRs, as appropriate. Follow-
up datawere expressed asmedians and IQRs andwere compared with
the Kruskal–Wallis test. The Wilcoxon signed-rank test, McNemar
test, and Mann–Whitney test were used for within/between-group
comparisons, as appropriate. Changes in the follow-up period of main
clinical parameters were tested by means of the repeated-measures
analysis using linear intercept or mixed models, adjusted for the base-
line value.
Estimated GFR was calculated using the Chronic Kidney Disease
Epidemiology Collaboration36 study equation for the adults and the
Schwartz formula for the children.37 Percentiles and z scores based on
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the US Centers for Disease Control and Prevention Growth Reference
Year 2000 were used to assess anthropometric measures to help eval-
uate children’s growth. Height D z score was deﬁned as the difference
between height z score of the period and midparental height z score
(target height z score). Changes over the 36-month observation be-
fore and after rituximab treatment were tested using linear mixed-
effect models and the slopes were compared using paired t test. All
P values were two sided. Analyses were carried out using SAS (version
9.1) and Stata (version 12).
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